Design Therapeutics, Inc.
No trades
No trades
Price target
21.000.000.00%
The 6 analysts offering 1-year price forecasts have a max estimate of — and a min estimate of —.
Analyst rating
Based on 7 analysts giving stock ratings in the past 3 months.
EPS
Reported
Estimate
Metrics
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Metrics
Reported
Estimate
Surprise
This is not investment advice and doesn't take into account your personal circumstances. It isn't a recommendation to buy, sell, or hold any asset. See the Terms of Use and always do your own research.
Frequently asked questions
The current price of DSGN is 12.87 USD — it has increased by 2.53% in the past 24 hours. Watch Design Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Design Therapeutics, Inc. stocks are traded under the ticker DSGN.
DSGN stock has fallen by −14.68% compared to the previous week, the month change is a −19.86% fall, over the last year Design Therapeutics, Inc. has showed a 113.70% increase.
We've gathered analysts' opinions on Design Therapeutics, Inc. future price: according to them, DSGN price has a max estimate of 22.00 USD and a min estimate of 20.00 USD. Watch DSGN chart and read a more detailed Design Therapeutics, Inc. stock forecast: see what analysts think of Design Therapeutics, Inc. and suggest that you do with its stocks.
DSGN reached its all-time high on Mar 26, 2021 with the price of 50.50 USD, and its all-time low was 1.94 USD and was reached on Aug 22, 2023. View more price dynamics on DSGN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
DSGN stock is 4.44% volatile and has beta coefficient of 0.89. Track Design Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Design Therapeutics, Inc. there?
Today Design Therapeutics, Inc. has the market capitalization of 785.40 M, it has decreased by −9.47% over the last week.
Yes, you can track Design Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Design Therapeutics, Inc. is going to release the next earnings report on Nov 11, 2026. Keep track of upcoming events with our Earnings Calendar.
DSGN earnings for the last quarter are −0.32 USD per share, whereas the estimation was −0.34 USD resulting in a 7.05% surprise. The estimated earnings for the next quarter are −0.34 USD per share. See more details about Design Therapeutics, Inc. earnings.
Design Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
DSGN net income for the last quarter is −20.16 M USD, while the quarter before that showed −17.64 M USD of net income which accounts for 0.00% change. Track more Design Therapeutics, Inc. financial stats to get the full picture.
No, DSGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 22, 2026, the company has 124 employees. See our rating of the largest employees — is Design Therapeutics, Inc. on this list?
Like other stocks, DSGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Design Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Design Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Design Therapeutics, Inc. stock shows the buy signal. See more of Design Therapeutics, Inc. technicals for a more comprehensive analysis.